Arkstone Study Demonstrates Power of AI in the Treatment of Bacteremia

BOCA RATON, Fla., May 28, 2025 /PRNewswire/ -- Arkstone Medical Solutions is proud to announce the publication of a groundbreaking peer-reviewed study in Life (MDPI), titled "AI-Based Treatment Recommendations Enhance Speed and Accuracy in Bacteremia Management." This research highlights the transformative impact of Arkstone's artificial intelligence (AI) and machine learning (ML) driven clinical decision support system (CDSS) on treating bloodstream infections (BSIs), particularly in resource-limited settings facing rising antimicrobial resistance (AMR).

The study, conducted in collaboration with Clinical Laboratory Roe in Lima, Peru, involved 117 patients diagnosed with bacteremia. Researchers compared Arkstone's OneChoice Molecular Report (AOCHMR), which utilizes only molecular data in its clinical recommendations, to its OneChoice Fusion Report (AOCHFR), which combines both molecular and phenotypic data into its clinical recommendations.

Key findings of the study include:

• AOCHMR delivered accurate therapeutic recommendations 29 hours faster than traditional phenotypic methods.
  
  
• A high concordance rate of 80.3% was observed for primary therapeutic recommendations between AOCHMR and AOCHFR.
  
  
• Pathogen and resistance detection agreement between molecular and culture testing modalities was 86.3%.
  
  
• Escherichia coli, the most prevalent organism identified, showed a remarkable 95% concordance between both testing modalities, highlighting the efficacy of molecular testing in guiding clinical treatment for bacteremia.

The study emphasizes the critical role AI and ML technologies can play in clinical settings, particularly where traditional culture-based diagnostics have lagging turnaround times and other limitations. Arkstone's OneChoice system, leveraging molecular data alone, empowers clinicians to promptly administer accurate treatments for severe infections like sepsis or bacteremia.

"This research marks a major milestone for Arkstone's mission: to deliver faster, more precise, and more accessible antimicrobial stewardship through clinical decision support," said Dr. Ari Frenkel, Chief Science Officer at Arkstone and co-author of the study. "With infectious diseases like sepsis, time is of the essence. Getting effective treatment started even one day earlier, let alone 29 hours earlier, can dramatically change patient outcomes."

"This is among the first studies to rigorously assess the reliability of molecular diagnostics integrated with AI-driven CDSS compared to traditional phenotypic testing," said Dr. Juan C. Gomez de la Torre, Director of Molecular Informatics and Clinical Research at Arkstone and Medical Director at Roe Laboratory. "Our findings affirm that molecular diagnostics, when combined with robust antimicrobial stewardship, offer timely, precise guidance without compromising clinical accuracy."

Arkstone's research provides a promising pathway for enhancing infectious disease management globally, especially in regions burdened by high AMR rates and limited laboratory infrastructure.

The full article is accessible at: https://www.mdpi.com/2075-1729/15/6/864

About Arkstone

Arkstone is a global leader in infectious disease clinical guidance and antimicrobial stewardship. Through its AI-enhanced (Antimicrobial Intelligence) solutions, Arkstone provides evidence-based, patient-specific recommendations to combat antibiotic misuse and antimicrobial resistance, ensuring smarter, safer prescribing decisions worldwide.

For more information, visit www.arkstone.ai or contact [email protected].

Media Contact

Sol Levi
1-833-933-ARK-3
[email protected]

SOURCE Arkstone